Actively Recruiting

Age: 18Years +
All Genders
NCT06838845

An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)

Led by AbbVie · Updated on 2025-11-26

80

Participants Needed

3

Research Sites

85 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Ulcerative colitis (UC) is a chronic, relapsing, and incurable inflammatory disease of the large intestine. The hallmark clinical symptoms include bloody diarrhea associated with rectal urgency and tenesmus.. This study will assess how effective upadacitinib is in treating UC within a Chinese population. Upadacitinib is an approved drug for treating UC. Approximately 80 adult participants, who have been prescribed upadacitinib for UC by their physician in accordance with local label, will be enrolled in China. Upadacitinib will be administered in accordance with the terms of the local marketing authorization, and treatment of participants will be determined solely by the investigator. Participants in the study will be followed for up to 1 year. There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and only data which are routinely collected during a regular visit will be utilized for this study.

CONDITIONS

Official Title

An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Chinese adults aged 18 years or older
  • Diagnosed with moderate to severely active ulcerative colitis
  • Prescribed upadacitinib by treating physicians following local label
  • Provided written authorization to use personal and health data before study entry
Not Eligible

You will not qualify if you...

  • Currently participating in any interventional clinical trials
  • Have any contraindication to upadacitinib as listed in the local China label
  • Unwilling or unable to comply with study requirements, including completing patient questionnaires

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

The First Affiliated Hospital, Sun-Yat Sen University /ID# 272997

Guangzhou, Guangdong, China, 510080

Actively Recruiting

2

The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 274753

Guangzhou, Guangdong, China, 510655

Actively Recruiting

3

The Second Affiliated Hospital Of Zhengzhou University /ID# 274754

Zhengzhou, Henan, China, 450014

Actively Recruiting

Loading map...

Research Team

Y

Yuting Xie

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) | DecenTrialz